Clinical trials: Graft-vs-host Disease
Acute Gastrointestinal Graft-versus-host Disease
Prospective Randomized Controlled Study: Amimaitosai Injection Combined With Corticosteroids for Gastrointestinal aGVHD
This study focuses on patients with gastrointestinal-dominant acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT07803978
- Testing
- Amimaitosai injection, Methylprednisolone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Cholecystitis, Chronic
Body First Approach in Lap Cholecystectomy in Cases With Obscure Calot's Triangle
The aim of this study is to evaluate the body first approach on the rate of conversion to open technique \& VBI in patients with obscure calot's triangle.
- Trial name
- NCT06280404
- Testing
- Lap cholecystectomy
- Volunteers
- 30 people
- Sponsor
- Assiut University
AML
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell…
- Trial name
- NCT06973668
- Testing
- Mycophenolate Mofetil, Ruxolitinib
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease, GVHD
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
This study will test PANO in combination with tacrolimus/sirolimus (TAC/SIR) for acute GVHD prevention. The purpose of this study is to determine if Panobinostat (PANO) when used in combination with sirolimus and tacrolimus will…
- Trial name
- NCT02588339
- Testing
- Panobinostat, Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia
This multicenter, prospective phase III-study is to compare the administration of ATG FRESENIUS to the NON-administration of ATG FRESENIUS in a myeloablative conditioning regimen followed by allogeneic hematopoeitic stem cell…
- Trial name
- NCT00678275
- Testing
- ATG FRESENIUS (Anti-Lymphocyte-Globulin)
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Hepatitis C, Chronic
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a…
- Trial name
- NCT00062816
- Testing
- ISIS 14803, peginterferon alfa, ribavirin
- Where
- 25 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Graft-versus-host Disease
Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
This is a single-center Phase I study to determine the maximum tolerated dose and safety of Neihulizumab for the treatment of Minnesota standard-risk aGVHD.
- Trial name
- NCT04144036
- Testing
- Neihulizumab, 3 mg/kg, Neihulizumab, 6 mg/kg, Neihulizumab, 9 mg/kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sameem M. Abedin, MD
Hematopoetic Stem Cell Transplant
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients
The objective of this study is to determine the maximum tolerated dose (MTD) of bortezomib in combination with calcineurin inhibitor and methotrexate as acute graft versus host disease (aGVHD) prophylaxis in pediatric patients…
- Trial name
- NCT01926899
- Testing
- Bortezomib administration
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Graft Versus Host Disease, Hematologic Malignancies
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD) after non-myeloablative transplantation can be reduced by using a combination of three immune suppressive medication; sirolimus…
- Trial name
- NCT00146614
- Testing
- Sirolimus, Tacrolimus, Methotrexate
- Where
- 3 sites in United States
- Volunteers
- 105 people
- Sponsor
- Dana-Farber Cancer Institute
Wounds
Clinical Validation of a 'Hand-held' Fluorescence Digital Imaging Device for Wound Care Applications
The primary objective of this clinical study is to evaluate the use and effectiveness of our 'handheld' fluorescence digital imaging device platform for real-time non-invasive clinical monitoring of chronic wounds for healing and…
- Trial name
- NCT01378728
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University Health Network, Toronto
Stroke
Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Stroke
Stroke is one of the leading causes of disability in the world, and stem cell - transplantation provides a promising approach for rehabilitation.
- Trial name
- NCT01714167
- Testing
- intracerebral stem cell transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wenzhou Medical University
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
The purpose of this study is to determine whether duvortuxizumab and ibrutinib can be combined safely and to establish the maximum tolerated dose (MTD) in Part 1 and the recommended Phase 2 dose (RP2D) and to further explore the…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell
- Trial name
- NCT02743546
- Testing
- Duvortuxizumab, Ibrutinib
- Sponsor
- Janssen Research & Development, LLC
Transfusion Dependent Thalassemia
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Graft-versus-host disease (GVHD) is a major factor affecting the efficacy and quality of life of alternative donor transplantation in thalassemia major (TM), severely limiting the clinical application of alternative donor…
- Trial name
- NCT06657391
- Testing
- recombinant humanized anti-CD25 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- Rongrong Liu
Hematologic Malignancies
Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
This is a randomized trial for patients undergoing hematopoietic progenitor cell transplantation (HPCT) from an unrelated donor.
- Trial name
- NCT01217723
- Testing
- Anti-Thymocyte Globulin (Rabbit), Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)
- Where
- 10 sites in Canada
- Volunteers
- 198 people
- Sponsor
- McMaster University
Fecal Microbiota Transplantation
Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer
Patients who have a gastrointestinal acute Graft versus host disease (GVHD) received a first-line standard treatment of corticosteroids. For patients who do not respond or progress after an initial response have a high mortality.
- Trial name
- HERACLES (NCT03359980)
- Testing
- fecal microbiota transfer
- Where
- 16 sites in France, Italy and 1 more
- Volunteers
- 24 people
- Sponsor
- MaaT Pharma
Lymphocytic Leukemia, Chronic
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with refractory chronic lymphocytic leukemia.
- Trial name
- NCT00431873
- Testing
- MGCD0103
- Where
- 13 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Mirati Therapeutics Inc.
Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific
Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant
RATIONALE: Thalidomide may interfere with the body's ability to recognize transplanted bone marrow cells as foreign and may help treat patients with graft-versus-host disease.
- Conditions
- Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003894
- Testing
- thalidomide
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Roswell Park Cancer Institute
Blood Cancer
Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving treatment for many malignant hematologic diseases.
- Trial name
- GUT-PREDICTION (NCT07305090)
- Testing
- Adult and pediatric patients with hematological diseases treated with allogeneic hematopoietic cell transplantation
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Immunosuppression, Leukemia
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor s T cells (a type of lymphocyte, or white blood cell) have been removed and then added back.
- Trial name
- NCT00353860
- Testing
- SOLEX 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Graft Versus Host Disease
Detection of Graft Versus Host Disease With [18F]F-AraG
This is a single-center imaging study to determine utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy…
- Trial name
- NCT03367962
- Testing
- [18F]F-Ara-G
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- CellSight Technologies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.